Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty

Summary

Hormone replacement therapy has been associated with venous thromboembolism. Controversy exists regarding the appropriate management of hormone replacement in the perioperative setting and in other situations – such as acute illness – predisposing to acute venous thromboembolism. We performed a case-control study to determine whether perioperative hormone replacement is associated with venous thromboembolism following hip and knee arthroplasty. 108 patients with postoperative venous thrombosis were matched by age, date and type of surgery, and surgeon with 210 controls without thrombosis. Perioperative hormone replacement use was no more prevalent in patients with postoperative thrombosis than those without. Eighteen (16.7%) women with post-operative thrombosis had taken perioperative hormone replacement compared to 49 (23.3%) of controls: odds ratio = 0.66; (95% CI 0.35–1.18; p=0.17). After multivariate analysis, the adjusted odds ratios were similar. Variables predicting post-operative thrombosis included: prior venous thromboembolism (OR = 2.3; p = 0.02), rheumatologic disease (OR = 2.2; p = 0.03), and absence of pharmacologic antithrombotic prophylaxis (OR = 13.4; p = 0.005). Cases and controls were otherwise similar. Users of hormone replacement were similar to non-users except that they were less likely to have coronary disease (OR 0.34; p = 0.03) or prior thrombosis (OR = 0.28; p = 0.04), and were younger (median age 67 versus 74 years; p <0.0001). We found no association between perioperative hormone replacement and post-operative thrombosis in patients undergoing major orthopaedic surgery. Routine discontinuation of these medications preoperatively – and possibly in other situations predisposing to thrombosis, such as acute medical illness – may be unnecessary in patients receiving appropriate pharmacologic antithrombotic prophylaxis.

Keywords

Hormone replacement therapy - selective oestrogen receptor modulator - venous thromboembolism - surgery - arthroplasty

• References

• 1 Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291: 47-53.
• 2 Riggs BL, Hartmann LC. Selective estrogenreceptor modulators – mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-629.
• 3 Grady D, Wenger NK, Herrington D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-696.
• 4 Daly E, Vessey MP, Hawkins MM. et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
• 5 Jick H, Derby LE, Myers MW. et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-983.
• 6 Grodstein F, Stampfer MJ, Goldhaber SZ. et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-987.
• 7 Morris BA, Colwell CW, Hardwick ME. The use of low molecular weight heparins in the prevention of venous thromboembolic disease. Orthop Nurs. 1998 17. 23-29. 77; quiz 30-1.
• 8 Geerts WH, Heit JA, Clagett GP. et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S-175S.
• 9 Heit JA, Berkowitz SD, Bona R. et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thromb Haemost 1997; 77: 32-38.
• 10 Spell 3rd NO. Stopping and restarting medications in the perioperative period. Med Clin North Am 2001; 85: 1117-1128.
• 11 Anonymous. Drugs in the peri-operative period: Hormonal contraceptives and hormone replacement therapy. Drug Ther Bull 1999; 37: 78-80.
• 12 Greer IA, Walker ID. Hormone replacement therapy and venous thromboembolism. Climacteric 1999; 02: 224-231.
• 13 THRIFT Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. BMJ 1992; 305: 567-574.
• 14 Robinson GE, Burren T, Mackie IJ. et al. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. BMJ 1991; 302: 269-271.
• 15 Bailar J. Hormone-replacement therapy and cardiovascular diseases. N Engl J Med 2003; 349: 521-522.
• 16 Robinson KS, Anderson DR, Gross M. et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med 1997; 127: 439-445.
• 17 Verlato F, Bruchi O, Prandoni P. et al. The value of ultrasound screening for proximal vein thrombosis after total hip arthroplasty – a prospective cohort study. Thromb Haemost 2001; 86: 534-537.
• 18 Kearon C, Julian JA, Newman TE. et al. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998; 128: 663-677.
• 19 Wells PS, Lensing AW, Davidson BL. et al. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. A meta-analysis. Ann Intern Med 1995; 122: 47-53.